Alnylam Pharmaceuticals
ALNY
#438
Rank
S$69.03 B
Marketcap
S$522.56
Share price
0.01%
Change (1 day)
53.45%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): S$0.11

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$0.12. In 2023 the company made an earnings per share (EPS) of S-$4.56 an increase over its 2022 EPS that were of S-$12.00.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$0.11
2023S-$4.56-62%
2022S-$12.0029.03%
2021S-$9.30-3.36%
2020S-$9.62-8.48%
2019S-$10.527.67%
2018S-$9.7739.74%
2017S-$6.9912.94%
2016S-$6.1938.84%
2015S-$4.46-32.88%
2014S-$6.64259.44%
2013S-$1.85-31.25%
2012S-$2.69

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
S-$1.61-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
S$56.12 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$3.54-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.31-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.94-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
S$9.51 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$4.79 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
S$0.81 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel